Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Feb 24, 2023 2:13pm
146 Views
Post# 35303975

Midatech Share Price Is Dropping

Midatech Share Price Is DroppingMidatech's share price has been dropping from 76.5¢ on February 9th, the day that Midatech announced its new financing at an initial proice of 58¢ per unit. As I write this, the Midatech share price is down 33% to 50.8¢.

The financing could be priced as low as 30¢ per unit dependent on share price. Dependent on certain shareholder approvals, certain aspects of the financing could be priced as low as 10¢ per unit. This would essentially wipe out current Midatech shareholders who would then have ~5% ownership of Midatech.

If there is a Bioasis deal coming with those almost worthless Midatech shares, then current Bioasis shareholders could end up with 2% or 3% of the resulting company, with no guarantee that the resulting company will retain much of any ownership of xB3.

By any definition, this would be a wiping out of Bioasis shareholder ownership of xB3. 

Why is the Midatech share price dropping? Is it the market and the S&P Biotech EGF or might there be motive for others to do it?

jd
<< Previous
Bullboard Posts
Next >>